Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-155-7 | CAS number: 116-75-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral administration to Wistar rats at doses of 100, 300 and 1000 mg/kg/day, for 28 days resulted in no substance related deaths, no clinical symptoms (at daily or weekly observations), no clinical symptoms (at the functional observational battery), no effects on food consumption or body weight development, no effects upon hematology and clinical biochemistry parameters, no changes in mean absolute or relative organ weights, and no macroscopical or microscopical findings of toxicological relevance.
Based on the results of this study, 1000 mg/kg body weight/day was established as the no-observed-adverse-effect-level (NOAEL) for the test substance.
Repeated dermal toxicity:
The dermal route was waived. The substance is considered not to exert adverse effects.
Repeated inhalation toxicity:
The inhalation route was waived. The substance is considered not to exert adverse effects.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: well performed GLP compliant OECD guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Italia S.p.A., Calco (Lecco), Italy
- Age at study initiation: approximately 7-8 weeks
- Weight at study initiation: 223-230 g
- Fasting period before study: no
- Housing: 5 sex/cage
- Diet (e.g. ad libitum): ad libitum, except for clinical pathology investigations
- Water (e.g. ad libitum): ad libitum, except for clinical pathology investigations
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C +/- 2°C
- Humidity (%): 55% +/- 15%
- Air changes (per hr): approximately 15 to 20
- Photoperiod (hrs dark / hrs light): 12 /12
IN-LIFE DATES: From: 15 June 2012 To: 03 August 2012 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): solubility test
- Concentration in vehicle: 20, 60, 200 mg/ml
- Amount of vehicle (if gavage): 5 ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability was found to be 24 hours at room temperature in the concentration range of 20 to 200 mg/mL.
Samples of the formulations prepared on Day 1 and on Week 4 of the study were also analysed to check the concentration and homogeneity. Results of the analyses were within the limits of acceptance.
Chemical analyses were carried out by the Analytical Chemistry Department at RTC, using a validated spectrophotometric detection in the range from 1.0 to 250 mg/mL.
The software used for this activity was Empower Probuild No. 2154. - Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg bw
Basis:
actual ingested - No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected in agreement with the Sponsor based on information from a preliminary, non GLP compliant RTC dose range finding study.
The purpose of this study was to investigate the toxicity of the test substance in rats after daily oral administration for 4 weeks and recovery from any treatment-related effects during a recovery period of 2 weeks (conrol and high dose group). - Positive control:
- not necessary
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: three times weekly
- Cage side observations checked in table yes
CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: on the day of allocation to treatment groups, on the day that treatment commenced, weekly thereafter and just prior to necropsy.
FOOD CONSUMPTION :
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, at weekly intervals following allocation
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Week 4 of treatment and Week 2 of recovery, just prior to necropsy
- Anaesthetic used for blood collection: Yes, under isofluorane
- Animals fasted: Yes
- How many animals: all animals
- Parameters examined:
Haematocrit
Haemoglobin
Red blood cell count
Reticulocyte count
Mean red blood cell volume
Mean corpuscular haemoglobin
Mean corpuscular haemoglobin concentration
White blood cell count
Differential leucocyte count
- Neutrophils
- Lymphocytes
- Eosinophils
- Basophils
- Monocytes
- Large unstained cells
Platelets
Prothrombin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Week 4 of treatment and Week 2 of recovery, just prior to necropsy
- Animals fasted: Yes
- How many animals: all animals
- Parameters examined:
Alkaline phosphatase
Alanine aminotransferase
Aspartate aminotransferase
Gamma glutamyltransferase
Urea
Creatinine
Glucose
Triglycerides
Bile acids
Inorganic Phosphorus
Total bilirubin
Total cholesterol
Total protein
Albumin
Globulin
Albumin/Globulin Ratio
Sodium
Potassium
Calcium
Chloride
URINALYSIS: Yes
- Time schedule for collection of urine: Week 4 of treatment, just prior to necropsy
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters examined:
Appearance
Volume
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
The sediment, obtained from centrifugation at approximately 3000 rpm for 10 minutes, was examined microscopically for:
Epithelial cells
Leucocytes
Erythrocytes
Crystals
Spermatozoa and precursors
Other abnormal components
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Weekly
- Dose groups that were examined: All
- Battery of functions tested: sensory activity / grip strength / motor activity / open field observations - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Euthanasia
Animals that had completed the scheduled test period were killed by exsanguination under isofluorane anaesthesia.
All animals were subjected to necropsy, supervised by a pathologist, as detailed below.
Necropsy
The clinical history of the animals was studied and a detailed post mortem examination was conducted (including examination of the external surface and orifices). Changes were noted, the requisite organs weighed and the required tissue samples preserved in fixative and processed for histopathological examination.
Organ weights
From all animals completing the scheduled test period, the organs indicated below were dissected free of fat and weighed.
The ratios of organ weight to body weight were calculated for each animal.
Tissues fixed and preserved
Samples of all the tissues listed below were fixed and preserved in 10% neutral buffered formalin (except eyes, testes and epididymides which were fixed in Modified Davidson's fluid and preserved in 70% ethyl alcohol).
Histopathological examination
The tissues required for histopathological examination are listed below. After dehydration and embedding in paraffin wax, sections of the tissues were cut at 5 micrometre thickness and stained with haematoxylin and eosin.
The examination was restricted as detailed below:
a) Tissues specified in the list below from all animals in the control and high dose groups killed after 4 weeks of treatment
b) All abnormalities in all main phase groups - Statistics:
- For continuous variables the significance of the differences amongst group means was assessed by analysis of variance. Differences between each treated group and the control group were assessed by Dunnett’s test using a pooled error variance. The homogeneity of the data was verified by Bartlett’s test. If the data were found to be heterogeneous, a modified t test (Cochran and Cox) was applied.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Dosing phase: An increase in monocytes value was observed in some females receiving 1000 mg/kg/day. Recovery phase At the end of the recovery period, the monocytes value of the treated females was comparable to the control group.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Dosing phase: An increase in phosphorus was recorded in a few animals from all treated groups. Recovery phase: After 2 weeks of recovery period, phosphorus value of treated animals was comparable with controls.
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- No clinical signs of toxicological significance were observed during treatment or recovery phases.
During the treatment period, neurotoxicity assessment (including motor activity and sensory reaction to stimuli), body weight and food consumption of treated groups did not show relevant signs, when compared to the control group.
Also during the recovery period, all the above parameters of the treated groups were comparable to the control group.
At haematological evaluation performed at the end of the treatment period, monocytosis was recorded in some females receiving 1000 mg/kg/day. In the absence of other clinical pathology and/or histopathological related changes and due to the inconsistency between sexes, the above findings was considered of no toxicological importance. At the end of the recovery period, monocytosis was no longer observed.
At clinical chemistry evaluation the principal alteration was an increase in phosphorus value (14% to 35%) in a few animals from all treated groups. But changes were not dose-related and were no longer observed at the end of the recovery period. Therefore changes were considered of no toxicological importance.
Terminal body weights, absolute and relative organ weights of treated animals were comparable to the control group both in dosing and recovery phases.
No findings of toxicological significance were observed at macroscopic observations.
No treatment-related lesions were noted at microscopic observations. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed up to the highest dose tested
- Critical effects observed:
- not specified
- Conclusions:
- On the basis of the above mentioned results 1000 mg/kg/day of the test item was established as the NOAEL (No Observed Adverse Effect Level) for animals of both sexes.
- Executive summary:
Study design
The toxicity of the test item was investigated, when given orally to rats for 4 weeks followed by a recovery period of 2 weeks. During the recovery period, no treatment was given to the recovery animals.
Each group comprised 5 male and 5 female rats, while control and high dose groups included 5 additional animals per sex to be sacrificed after 2 weeks of recovery.
The test item was administered by oral gavage at a dose volume of 5 mL/kg.
Group
Number
Treatment
(mg/kg/day)
Number of animals
1
2
3
4
0
100
300
1000
10M+10F
5M+5F
5M+5F
10M+10F
M = Males; F = Females
The following investigations were performed: daily clinical signs, neurotoxicity assessment (weekly detailed clinical examinations, motor activity and sensory reactivity to stimuli), body weight, food consumption, clinical pathology investigations, organ weights, macroscopic observations and histopathological examination.
Mortality
No animals died during the study.
Clinical signs and observation of the cage tray
Dosing phase and recovery phase
The clinical sign noted throughout the study (blue staining of the body surface) was clearly related to the blue colour of the test item.
Observation of the cage tray
As consequence of the colour of the test item, light blue staining was observed on the cage tray in animals of both sexes receiving the dose level ≥ 300 mg/kg/day.
1.4 Neurotoxicity assessment – Detailed clinical examination
Dosing phase and recovery phase
Observation of animals at removal from the cage and in an open arena (neurotoxicity assessment) did not reveal changes attributable to the test item throughout the study.
1.5 Body weight
Dosing phase and recovery phase
No difference in body weights was recorded in animals of both sexes compared to the control group, throughout the study.
Food consumption
Dosing phase and recovery phase
Food consumption did not show any differences between control and treated groups, during both treatment and recovery periods.
Motor activity
Dosing phase and recovery phase
Motor activity, performed at the end of the treatment and recovery periods, did not show particular differences between the control and treated groups in both sexes.
Sensory reactivity to stimuli
Dosing phase and recovery phase
Sensory reactivity to stimuli, recorded at the end of treatment and recovery periods, was comparable between control and treated groups.
Haematology
Dosing phase
An increase in monocytes value was observed in some females receiving 1000 mg/kg/day. In the absence of other clinical pathology and/or histopathological related changes and due to the inconsistency between sexes, the above finding was considered of no toxicological importance.
Recovery phase
At the end of the recovery period, the monocytes value of the treated females was comparable to the control group.
Clinical chemistry
Dosing phase
An increase in phosphorus was recorded in a few animals from all treated groups. Changes were less severe, not dose-related and not evident in the recovery group. Therefore changes were considered of no toxicological importance.
Recovery phase
After 2 weeks of recovery period, phosphorus value of treated animals was comparable with controls.
Urinalysis
Dosing phase
No changes in urine parameters were observed in treated animals when compared to the control group.
Terminal body weight and organ weights
Final sacrifice and recovery sacrifice
Terminal body weight in treated animals did not show any differences between control and treated groups, both in dosing and recovery phases.
Final sacrifice
Absolute and relative organs weights
No intergroup differences in organ weights were observed in treated groups, when compared to controls.
Recovery sacrifice
Absolute and relative organs weights
No differences were observed between control and treated groups.
Macroscopic observations
Final sacrifice
The macroscopic findings observed at post mortem examination (blue staining in the mucosa of non glandular region of the stomach, in the caecum and on the skin and the tail surface) were clearly related to the colour of the test item administered.
Recovery sacrifice
No treatment-related macroscopic changes were noted.
Microscopic observations
Final sacrifice
No treatment-related lesions were noted.
Conclusions
On the basis of the above mentioned results, 1000 mg/kg/day of the test item was established as the NOAEL (No Observed Adverse Effect Level) for animals of both sexes.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- reliable without restrictions - well performed GLP compliant OECD guideline study
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
no alternative study available
Justification for classification or non-classification
The submission substance does not have to be classified regarding systemic and target organ toxicity after repeated oral exposure according to the criteria laid down in Directive 67/548/EEC and in Regulation (EC) No 1272/2008, because:
- The submission substance caused no relevant systemic effects and revealed an NOAEL of 1000 mg/kg/day (which is the highest dose tested) in a Repeated Dose Toxicity Test after oral application.
It can reasonably be deduced that the submission substance does not exert systemic toxic effects after repeated dermal application and thus does not have to be classified according to the criteria laid down in Directive 67/548/EEC and in Regulation (EC) No 1272/2008 and that testing is not scientifically necessary, because:
- The submission substance caused no relevant systemic effects and revealed an NOAEL of 1000 mg/kg/day in a Repeated Dose Toxicity Test after oral application,
- it is unlikely that the submission substance becomes systemically bioavailable to a relevant extend after dermal exposure due to its low solubility in water and n-octanol,
- the repeated dose toxicity after dermal application is not considered to be higher than after oral administration,
- testing for acute dermal toxicity revealed no signs of bioavailability or toxicity.
- the submission substance does not have to be classified as skin sensitizing or as skin or eye irritating, indicating that its chemical inertness and low solubility in water and n-octanol largely prevent interaction with living cells and tissues.
It can reasonably be deduced that the submission substance does not exert systemic toxic effects after repeated inhalation exposure and thus does not have to be classified according to the criteria laid down in Directive 67/548/EEC and in Regulation (EC) No 1272/2008 and that testing is not scientifically necessary, because:
- the submission substance caused no relevant systemic effects and revealed an NOAEL of 1000 mg/kg/day in a Repeated Dose Toxicity Test after oral application,
- it is unlikely that the submission substance becomes systemically bioavailable to a relevant extend after inhalation due to its low solubility in water and in n-octanol,
- the submission substance does not have to be classified as skin sensitizing or as skin or eye irritating, indicating that its chemical inertness and low solubility in water and in n-octanol largely prevent interaction with living cells and tissues,
- the submission substance, when aerosolized in respirable form, is likely to behave like an inert dust.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.